

Drug Monograph

Drug/Drug **Digoxin 0.25mg/5ml oral solution / cardiac glycoside**

Class:

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.	
Dosage Forms:	Each milliliter of Digoxin solution contains 0.05mg of digoxin.	
Manufacturer:	Precision Dose, Inc. 722 Progressive Lane, South Beloit, IL 61080	
Indications:	Digoxin is indicated for ventricular rate control in patients with chronic atrial fibrillation and/or atrial flutter, for the treatment of narrow-complex paroxysmal supraventricular tachycardia (PSVT) or for paroxysmal supraventricular tachycardia (PSVT) prophylaxis in patients without a delta wave on ECG during sinus rhythm, or for the treatment of congestive heart failure.	
Costs:	\$4.20 per pack of 5 cups of digoxin solution. Wholesale Acquisition Cost	
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.	
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required	<input checked="" type="checkbox"/> Open Access
	<input type="checkbox"/> Clinical Edit	<input type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE	<input type="checkbox"/> Preferred Agent
	<input type="checkbox"/> Appropriate Indications	<input checked="" type="checkbox"/> No Prior Authorization Required

Prepared By: Ashley Capps, Pharm.D. Candidate

Date: August 21, 2012